Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

B oth men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)-a chronic inflammatory ...

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...